GSK vs ORGO · P/E 13, $103.31B cap vs rev $81.0M
GlaxoSmithKline PLC ADR (GSK) versus Organogenesis Holdings Inc (ORGO) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Organogenesis Holdings Inc (ORGO) is a drug manufacturers - specialty & generic company listed on NASDAQ.
GSK does not have a complete income-statement cache yet.
Latest reported ORGO revenue for 2026-06-30 was $81.0M. Net income was -$149.4M. ORGO currently screens at market cap $301.1M.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. ORGO currently screens at market cap $301.1M.
Not investment advice. Open the GSK and ORGO stock pages for the full models.
Not investment advice.